Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
JAMA Dermatology|July 21, 2018
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor TherapyLeo L Wang, Gopal Patel, Zelma C Chiesa-Fuxench, et al.
Journal of Translational Medicine|September 21, 2021
Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary eventsTim Jang, Maria Poplawska, Emanuela Cimpeanu, et al.
Immunity|January 1, 2026
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicityMinke W Lucas, Elizabeth M Burton, Petros Dimitriadis, et al.
Annals of Surgical Oncology|July 5, 2019
Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic TherapiesYun Song, Andrew D Tieniber, Phyllis A Gimotty, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanomaJeffrey C Thompson, Christiana Davis, Charuhas Deshpande, et al.
The Oncologist|September 5, 2020
Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell CarcinomaAnish A Butala, Varsha Jain, Vishruth K Reddy, et al.
Journal of the American Academy of Dermatology|November 28, 2022
Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysisCimarron E Sharon, Richard J Straker, Phyllis A Gimotty, et al.
Blood Reviews|July 26, 2021
Antibiotics to modify sickle cell disease vaso-occlusive crisis?Connor Stewart, Tim Jang, George Mo, et al.
Annals of Surgical Oncology|January 4, 2020
Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III MelanomaYun Song, Richard J Straker, Xiaowei Xu, et al.
Pageof 8